China’s Biopharma Homecoming
By James Strachan, Henry Thomas
September 1, 2026
Chinese biopharma leaders are returning from the West to build a more confident – and innovative – global industry, says Cyagen’s Lance Han
7 min read
False
Advertisement
Biopharma
Breaking Manufacturing Bottlenecks in Nucleic Acid Therapeutics
By David Butler
August 31, 2026
New approaches to oligonucleotide production, mRNA design, and supply chain control could help turn promising nucleic acid therapies into scalable commercial products
4 min read
The Hidden Complexity of Stability Storage
By Lori A. Ball
August 27, 2026
Why preserving samples is a scientific, regulatory, and operational challenge – and what’s at risk when it goes wrong
9 min read
Green Shoots, Gray Skies
By Olivia Anderson, James Strachan
August 26, 2026
Jon Rees sees signs of recovery following biotech's post-pandemic funding reset, but there’s no going back to the “old normal”
9 min read
Phase III Success Marks Milestone for Personalized Cancer Vaccines
August 26, 2026
Merck and Moderna report positive phase III results for intismeran in melanoma, as The Medicine Maker revisits how cancer vaccines work and the challenges still facing the field
7 min read
The Mindset for Success in Biopharma's New Multipolar World
By Jessica Allerton, James Strachan
August 18, 2026
From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market
10 min read
Biopharma Labs Have an Integration Debt Problem
By Mark Fish
August 17, 2026
Biopharma labs are investing heavily in digital tools, but without trusted data architecture, each new platform can add another point of failure
5 min read
Moving Glycosylation Control Upstream
August 6, 2026
Samsung Biologics’ Sojeong Lee discusses why biologics developers are paying closer attention to glycosylation earlier in development.
7 min read
How China Is Rewriting the Rules Global Drug Development
By James Strachan
August 5, 2026
In part two of our conversation, Lingshi Tan explores how China’s integrated biopharma ecosystem is reshaping assumptions about speed, cost, innovation, and cross-border clinical development
14 min read
The 10 Biggest Bottlenecks Slowing Drug Development
August 4, 2026
Ten industry leaders from the 2026 Power List identify the scientific, clinical, regulatory, and financial barriers holding drug development back
6 min read
